Abstracts Archive - Page 2311 of 2607 - ACR Meeting Abstracts

Abstract Number: 1841 • 2013 ACR/ARHP Annual Meeting
BAFF Induces Production of Matrix Metalloproteinase-9 By Peripheral Monocytes in Patients With Primary Sjögren’s Syndrome Through a Signaling Pathway That Involves NF-Kb and PI3 Kinase
Keiko Yoshimoto¹, Maiko Tanaka², Masako Kojima², Hideko Ogata², Eriko Ishioka³, Ayumi Nishikawa², Katsuya Suzuki¹, Hideto Kameda¹, Tohru Abe⁴ and Tsutomu Takeuchi⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Dept Int Med Saitama Med Ctr, Saitama Medical School, Kawagoe-shi Saitama, Japan, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: B cell activating factor of the TNF family (BAFF) regulates proliferation, differentiation and survival of B cells, and plays a pivotal role in the…
Abstract Number: 1842 • 2013 ACR/ARHP Annual Meeting
Pathophysiological Effects Of Free Fatty Acids On Key Cells Of Arthritis
Klaus W. Frommer¹, Andreas Schäffler², Stefan Rehart³, Angela Lehr⁴, Ulf Müller-Ladner¹ and Elena Neumann⁵, ¹Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²Department of Internal Medicine III, Endocrinology, Diabetes, Metabolism, Justus-Liebig-University of Giessen, Giessen, Germany, ³Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, ⁴Dept Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, ⁵Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany
Background/Purpose: Although obesity, a known risk factor for arthritic diseases, increases mechanical stress on joints, it appears not to be the only factor being responsible…
Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting
Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment
Edward Bernton¹ and Valerie Lowe², ¹Protalex Inc., Summit, NJ, ²Washington Biotechnology, Inc., Baltimore, MD
Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that is currently in Phase I trials in patients with active rheumatoid arthritis (RA). SpA…
Abstract Number: 1844 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Sjogren’s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies
Sarthak Gupta^1,2, Ioanna P. Tatouli³, Lindsey B. Rosen², Sarfaraz A. Hasni¹, Richard M. Siegel¹, Steven M. Holland², Haralampos M. Moutsopopoulos³ and Sarah K. Browne², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, the prevalence and significance of anticytokine autoantibodies in rheumatic conditions is poorly…
Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Taher Fatakdawala¹, Michael Skawinski¹, Jonathan Ferriera², Tara Stauffer¹ and Thomas Lavoie¹, ¹Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, ²Quality Control, PBL Assay Science, Piscataway, NJ
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…
Abstract Number: 1846 • 2013 ACR/ARHP Annual Meeting
Mitochondrial Dysfunction Induces An Inflammatory, Tissue-Degrading, and Angiogenic Response In Normal Human Synoviocytes
M. Noa Valcárcel-Ares¹, Romina R. Riveiro-Naveira¹, Jesus Loureiro¹, Carlos Vaamonde-García¹, Laura Hermida-Carballo¹, Francisco J. Blanco² and Maria J. López-Armada¹, ¹Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, ²Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain
Background/Purpose: Tissues affected with inflammatory arthritis (IA) are subjected to great levels of oxidative stress. Synoviocytes from IA patients present a higher rate of mitochondrial…
Abstract Number: 1847 • 2013 ACR/ARHP Annual Meeting
Certolizumab-Pegol Induces Reverse Signaling Through Membrane TNF Via Calcineurin Activation In Human Monocytes. Relevance In Inflammation
Jean-Frederic Boyer^1,2, Michel Baron³, Delphine Nigon¹, Arnaud L. Constantin¹, Alain G. Cantagrel^1,2 and Jean-Luc Davignon^2,4, ¹Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, ²INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Toulouse, France, ³Centre de Physiopathologie de Toulouse Purpan, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Toulouse, France, ⁴Rheumatology, Purpan University Hospital, Toulouse, France
Background/Purpose: Reverse signalling seems to play a role in the mode of action of anti-TNF-α agents but this pathway and its relevance are poorly understood.…
Abstract Number: 1813 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Effect Of Sildenafil On The Microvascular Blood Flow and On The Endothelial Progenitor Cells In Patients With Early Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
Fernando V. Andrigueti, Pâmela C.C. Ebbing, Maria I. Arismendi and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Phosphodiesterase-5 inhibitors have been successfully used for the treatment of Raynaud’s phenomenon (RP) in patients with systemic sclerosis (SSc). However, no study has evaluated…
Abstract Number: 1808 • 2013 ACR/ARHP Annual Meeting
Impact Of Baseline Disease Severity and Treatments On Outcomes In Clinical Trials Of SLE: Results From The Soccit Program
Kenneth C. Kalunian¹, Mimi Kim², Timothy W. Behrens³, Sabine Bongardt⁴, Paul Brunetta⁵, Paola Daly⁶, Nathalie Franchimont⁷, Richard Furie⁸, Matthew Linnik⁹, Bevra H. Hahn¹⁰, Leslie M. Hanrahan¹¹, Jan L. Hillson¹², Jane Salmon¹³, Neil Solomons¹⁴ and Joan T. Merrill¹⁵, ¹UCSD School of Medicine, La Jolla, CA, ²Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ³Genentech, Inc, South San Francisco, CA, ⁴UCB Pharma, Monheim, Germany, ⁵Biotherapeutics, Genentech, So San Francisco, CA, ⁶Lupus Foundation of America, Washington DC, DC, ⁷Biogen Idec Inc., Weston, MA, ⁸North Shore-LIJ Health System, Lake Success, NY, ⁹Lilly Research Laboratories, La Jolla, CA, ¹⁰Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ¹¹Education & Research, Lupus Foundation of America, Washington, DC, ¹²Bristol-Myers Squibb, Seattle, WA, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Vifor Pharma, New York, NY, ¹⁵Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The Lupus Foundation of America Collective Data Analysis Initiative was established to evaluate SLE clinical trial design, using data collected from multiple studies. To…
Abstract Number: 1809 • 2013 ACR/ARHP Annual Meeting
Topline Results Of The Biomarkers Of Lupus Disease (BOLD) Study: Clinical and Mechanistic Perplexities Of Lupus Treatment Trials Can Be Mitigated By Eliminating Background Immune Suppressants
Joan T. Merrill¹, Frederick W. Immermann², Tianhui Zhou³, Margot O'Toole⁴, Maryann Whitley⁵, Andrew A. Hill⁵, Ying Zhang⁵, David von Schack⁵, Padmalatha S. Reddy⁵, Jaime L. Masferrer⁴, Stan Kamp¹, Joel M. Guthridge⁶, Aikaterini Thanou⁷, Paul Wu⁵, Theresa Paradis⁵, William M. Mounts⁵, Judith A. James⁸ and Sudhakar T. Sridharan², ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²BioTherapeutics R&D, Pfizer Inc, Collegeville, PA, ³BioTherapeutics R&D, Bristol Myers Squibb, Princeton, NJ, ⁴independent consultant, Cambridge, MA, ⁵Pfizer Inc, Cambridge, MA, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis and Clinical Immmunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The BOLD study was designed to test the discriminatory capacity and safety of a trial design eliminating background immune suppressants (IS) in SLE patients…
Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Hebah Alhajeri¹, Marie Hudson², Marvin J. Fritzler³, Janet E. Pope⁴, Canadian Scleroderma Research Group -⁵ and Murray Baron⁶, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴St Joseph Health Care, London, ON, Canada, ⁵Jewish General Hospital, Montreal, QC, Canada, ⁶Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…
Abstract Number: 1811 • 2013 ACR/ARHP Annual Meeting
Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
Aaliya Yaqub¹, Lorinda Chung², David Fiorentino³ and Eswar Krishnan⁴, ¹Stanford Univ Medical Center, Stanford, CA, ²Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease associated with substantial morbidity. Epidemiologic studies using large administrative databases often rely on the accuracy of…
Abstract Number: 1812 • 2013 ACR/ARHP Annual Meeting
Adverse Events In Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared To Idiopathic Pulmonary Arterial Hypertension
Rennie L. Rhee¹, Nicole B. Gabler², Amy Praestgaard², Peter A Merkel³ and Steven M. Kawut⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Whether the risk of treatment-related adverse events (AEs) in patients with pulmonary arterial hypertension (PAH) differs based on diagnosis, either connective tissue disease (CTD-PAH)…
Abstract Number: 1814 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pulmonary Embolism and Deep Venous Thrombosis In Systemic Sclerosis: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Iman Hemmati², Eric C. Sayre³, Kamran Shojania^3,4 and Hyon Choi^3,5,6, ¹Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Deparment of Medicine and Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Data on the risk of pulmonary embolism (PE) and deep venous thrombosis (DVT) in patients with systemic sclerosis (SSc) is lacking. To fill this…
Abstract Number: 1815 • 2013 ACR/ARHP Annual Meeting
Asymmetric Dimethylarginine Levels In The Early Detection Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Vivek Thakkar¹, Wendy Stevens², David Prior³, Joanne Sahhar⁴, Janet E. Roddy⁵, Jane Zochling⁶, Peter Nash⁷, Peter Youssef⁸, Susanna Proudman⁹ and Mandana Nikpour¹⁰, ¹St Vincent's Hospital, Melbourne, Australia, ²Rheumatology, St Vincent's Hospital, Melbourne, Australia, ³Cardiology, St Vincent's Hospital, Melbourne, Australia, ⁴Rheumatology Unit, Monash Medical Centre, Clayton, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Menzies Research Institute Tasmania, Hobart, Australia, ⁷Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, ⁸Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia, ⁹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹⁰Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc), and alterations in nitric oxide (NO) metabolism and endothelial cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].